Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 17/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8043023 | 0.86 | KDM4E (0.52) | BCHEKDM4EL3MBTL1MEN1KMT2A | |
| SCHEMBL13888119 | 0.86 | BCHE (0.69) | BCHEKDM4EL3MBTL1MEN1KMT2A | |
| SCHEMBL28129636 | 0.85 | KDM4E (0.65) | BCHEKDM4EL3MBTL1 | |
| SCHEMBL12773202 | 0.85 | KDM4E (0.55) | BCHEKDM4EL3MBTL1MEN1KMT2A | |
| SCHEMBL21300617 | 0.85 | BCHE (0.67) | BCHEKDM4EL3MBTL1 | |
| SCHEMBL8964423 | 0.84 | BCHE (0.68) | BCHEKDM4EL3MBTL1MEN1KMT2A | |
| SCHEMBL9802381 | 0.84 | BCHE (0.68) | BCHEKDM4EL3MBTL1 | |
| SCHEMBL6035722 | 0.84 | BCHE (0.63) | BCHEKDM4EL3MBTL1MEN1KMT2A | |
| SCHEMBL4225323 | 0.83 | KDM4E (0.59) | BCHEKDM4EL3MBTL1MEN1KMT2A | |
| SCHEMBL28129637 | 0.82 | BCHE (0.61) | BCHEKDM4EL3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113307772-B | Human plasma kallikrein inhibitors | 拜奥克里斯特制药公司 | 2024-06-28 | — | — | CN | disclosed |
| CN-113307772-A | Human plasma kallikrein inhibitors | 拜奥克里斯特制药公司 | 2021-08-27 | — | — | CN | disclosed |
| CN-106257976-B | Human plasma kallikrein inhibitors | 拜奥克里斯特制药公司 | 2021-02-02 | — | — | CN | disclosed |
| CN-106257976-A | Human plasma kallikrein inhibitors | 拜奥克里斯特制药公司 | 2016-12-28 | — | — | CN | disclosed |
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
| EP-1513817-A1 | 1, 2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | Takeda Pharmaceutical Company Limited (JP) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003099793-A9 | 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA PHARMACEUTICAL (JP) | 2005-02-10 | — | — | WO | disclosed |
| CN-1564818-A | Stereoselective synthesis method of 2-hydroxymethyl-chroman | WYETH CORP (US) | 2005-01-12 | — | — | CN | disclosed |
| EP-1432695-A1 | A PROCESS FOR THE STEREOSELECTIVE SYNTHESIS OF 2-HYDROXYMETHYL-CHROMANS | Wyeth (US) | 2004-06-30 | — | — | EP | disclosed |
| US-6700001-B2 | USEFUL AS INTERMEDIATES TO DRUGS INCLUDING THOSE TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS; STEREOSPECIFIC CYCLIZATION OF AN OPTICALLY ACTIVE PHENOL COMPOUND | WYETH | 2004-03-02 | — | — | US | disclosed |
| US-20030100579-A1 | Antidepressant chroman and chromene derivatives of 3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole | WYETH | 2003-05-29 | — | — | US | disclosed |
| WO-2003031439-A1 | ANTIDEPRESSANT CHROMAN AND CHROMENE DERIVATIVES OF 3-(1,2,3,6-TETRAHYDRO-4-PYRIDINYL)-1H-INDOLE | WYETH (US) | 2003-04-17 | — | — | WO | disclosed |
| WO-2003031429-A1 | A PROCESS FOR THE STEREOSELECTIVE SYNTHESIS OF 2-HYDROXYMETHYL-CHROMANS | WYETH (US) | 2003-04-17 | — | — | WO | disclosed |
| US-5525614-A | TREATING VASCULAR RESTENOSIS, CNS DISORDERS | WARNER-LAMBERT COMPANY (US) | 1996-06-11 | — | — | US | disclosed |
| US-5489686-A | CARDIOVASCULAR DISORDER, NERVOUS SYSTEM DISORDER, ANTIDIURETIC , PSYCHLOGICAL DISORDER, ANTIDEPRESSANTS | WARNER-LAMBERT COMPANY (US) | 1996-02-06 | — | — | US | disclosed |
| EP-0641326-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINES WITH ANGIOTENSIN II RECEPTOR ANTAGONIST PROPERTIES | WARNER-LAMBERT COMPANY (US) | 1995-03-08 | — | — | EP | disclosed |
| US-5350757-A | Treatment of vascular restenosis, nervous system disorders and cognition enhancement | WARNER-LAMBERT COMPANY (US) | 1994-09-27 | — | — | US | disclosed |
| WO-1993023378-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINES WITH ANGIOTENSIN II RECEPTOR ANTAGONIST PROPERTIES | WARNER-LAMBERT COMPANY (US) | 1993-11-25 | — | — | WO | disclosed |
| US-5246943-A | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties | WARNER-LAMBERT COMPANY (US) | 1993-09-21 | — | — | US | disclosed |
| US-4994486-A | Neurological disorders | ABBOTT LABORATORIES (US) | 1991-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | GPR119, SLC5A1, CYP4B1 | BCHE 1107/4885KDM4E 509/4885L3MBTL1 1040/4885 |
| US-20030100579-A1 | Antidepressant chroman and chromene derivatives of 3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole | TPH1, HTR1D, HTR1A | BCHE 3226/4885KDM4E 1571/4885L3MBTL1 3759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.